Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 122, Issue 3, 2001, Pages 630-632

  Genoni, Michele ^a   Zeller, Daniela ^a   Bertel, O ^a   Maloigne, M ^a   Turina, M ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; AGGRESTAT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY SURGERY; FIBRINOLYSIS; HUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

EID: 0034854372     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2001.115691     Document Type: Article

References (5)

1. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
2. Inhibition of platelet glycoprotein IIb/IIIa in epitifibatide in patients with acute coronary syndromes
3. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty